摘要
目的检测人端粒酶逆转录酶(hTERT)、刺激蛋白1(Sp1)和原癌基因转录因子(c-myc)在良、恶性胰岛β细胞瘤和正常胰岛β细胞组织中的表达,探讨三者与胰岛β细胞瘤的关系,为临床鉴别良、恶性胰岛β细胞瘤和判断预后提供理论依据。方法用免疫组化方法检测hTERT、Sp1、c-myc在27例良性、16例恶性胰岛β细胞瘤和20例正常胰岛β细胞组织中的表达,并行相关性分析。结果 hTERT、Sp1、c-myc在恶性胰岛β细胞瘤中的阳性表达率分别为81.2%、75.0%、87.5%,在良性胰岛β细胞瘤中的阳性表达率分别为25.9%、29.6%、14.8%,在正常胰岛β细胞组织中没有表达。hTERT、Sp1和c-myc在良、恶性胰岛β细胞瘤的表达差异均有统计学意义(P均<0.05),且在恶性胰岛β细胞瘤的表达明显高于良性胰岛β细胞瘤和正常胰岛β细胞组织;hTERT与Sp1、c-myc的表达呈明显正相关(r分别为0.992、0.893,P均<0.01)。结论端粒酶的激活在良、恶性胰岛β细胞瘤的发生发展中起重要作用。联合检测hTERT、Sp1和c-myc的表达可作为鉴别良、恶性胰岛β细胞瘤的手段。
Objective To explore the expressions of hTERT, Spl and c-myc in the organization of islet cell tumor in benign and malignant tumor and normal pancreatic islet cells, and investigate the correlation between hTERT, Spl and c- myc and islet cell tumor, identifying benign and malignant islet tumor and providing theoretic basis for the prognosis of islet cells. Methods The expressions of hTERT, Spl and c-myc were detected by immunohistochemistry in islet cell tumor and normal pancreatic islet cells, and correlation analysis was carried out according to the data. Results In the malignant islet cell tumor, the expression rates of hTERT, Spl and c-my were 81.2%, 75.0%, 87.5%, respectively. By comparison, the expression rates of hTERT, Spl and c-my were respectively 25.9% , 29.6% , 14.8% in benign islet cells. While hTERT, Spl and c-my had no expression in normal pancreatic cell tissue. The expression differences of hTERT, Spl and c-myc in benign and malignant islet cell tumor are statistically significant （ P 〈 0.05 ）, and the expression of malignant islet cell tumor was significantly higher than that in the benign pancreatic islet cell tumor and normal pancreatic tissue. Further- more, there was a significant relationship among hTERT, Spl, c-myc （ r = 0. 992, 0. 893, both P 〈 0.01 ）. Conclusions The telomerase activation plays an important role in the appearance and growth of benign and malignant islet cell tumor. In the cell cycle, there are many ways to control the telomerase activity. Moreover, the joint inspection of hTERT, Spl and c-myc can be used as a method to identify benign and malignant isle cell tumor.
出处
《山东医药》
CAS
2012年第21期27-29,共3页
Shandong Medical Journal
